Insider Trading History of Gosling Matthew M


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Gosling Matthew M since year 2005. The trader's CIK number is 1367754. At the time of the last reporting, Gosling Matthew M was the VP, General Counsel of Assertio Therapeutics, Inc . (stock ticker symbol ASRT). See this page for all insider trading activities at Assertio Therapeutics, Inc .


Stock purchases, sales, and option exercises reported by insider Gosling Matthew M since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2018-05-11 DEPO Assertio Therapeutics, Inc Sale 19,674 7.07 139,095
2018-03-07 DEPO Assertio Therapeutics, Inc Sale 45,519 6.58 299,515
2017-05-11 DEPO Assertio Therapeutics, Inc Sale 59,212 11.37 673,299
2014-12-02 DEPO Assertio Therapeutics, Inc Sale 8,819 15.85 139,807
2014-11-19 DEPO Assertio Therapeutics, Inc Option Ex 71,000 6.17 438,070
2014-11-19 DEPO Assertio Therapeutics, Inc Sale 71,000 15.36 1,090,347
2014-05-09 DEPO Assertio Therapeutics, Inc Option Ex 4,000 6.17 24,680
2014-03-14 DEPO Assertio Therapeutics, Inc Option Ex 21,875 3.09 67,593
2014-03-14 DEPO Assertio Therapeutics, Inc Sale 21,875 14.73 322,328
2013-12-02 DEPO Assertio Therapeutics, Inc Sale 5,692 8.40 47,835
2012-12-12 DEPO Assertio Therapeutics, Inc Sale 65,702 5.84 383,831
2012-12-12 DEPO Assertio Therapeutics, Inc Option Ex 48,125 3.09 148,706
2012-12-06 DEPO Assertio Therapeutics, Inc Sale 2,615 5.80 15,167
2009-08-11 DEPO Assertio Therapeutics, Inc Option Ex 15,000 1.98 29,700
2009-08-11 DEPO Assertio Therapeutics, Inc Sale 27,724 3.67 101,691

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Gosling Matthew M (VP, General Counsel of Assertio Therapeutics, Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.